echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Opdivo of BMS beat keytruda of MSD for the first time in Q3 2015

    Opdivo of BMS beat keytruda of MSD for the first time in Q3 2015

    • Last Update: 2015-10-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: on October 30, 2015, both Bristol Myers Squibb and MSD announced the company's sales in the third quarter The sales data showed that the sales of opdivo, the PD-1 inhibitor of Bristol Myers Squibb, exceeded the sales of keytruda for the first time In the third quarter of 2015, opdivo (nivolumab), an inhibitor of PD-1, brought sales of $305 million to Bristol Myers Squibb, which was $160 million ahead of keytruda (pembrolizumab) of MSD The two drugs competed with each other in the field of melanoma and non-small cell lung cancer Up to now, the sales of opdivo and keytruda in 2015 are about 467 million US dollars and 352 million US dollars respectively, but the market performance of PD-1 inhibitor in the third quarter shows that Bristol Myers Squibb began to leave its competitors far behind This is in line with the forecast of some industry analysts, who have predicted that opdivo will lead the PD-1 inhibitor Market with annual sales of more than 8 billion US dollars in 2020, followed by MSD's products with annual sales of 5 billion US dollars or higher Giovanni caforio, CEO of Bristol Myers Squibb, said that the strong market performance of opdivo showed that opdivo was widely accepted by patients in the two treatment areas of squamous non-small cell lung cancer and melanoma, especially in the United States and Germany Doctors prescribe opdivo for three-quarters of new patients with squamous non-small cell lung cancer, Bristol Myers said This month, opdivo has no intention of acquiring the new indication of NSCLC in the United States, which is bound to promote its market share According to Adam Schechter, global head of human health at MSD, keytruda's sales in the third quarter increased by 45% compared with the second quarter, and it is particularly outstanding in the field of melanoma treatment, accounting for 70% of the market share of melanoma anti-PD-1 Opdivo seems to benefit from the treatment of non-small cell lung cancer, which is a much larger market than melanoma, because opdivo is approved as a second-line therapy for all patients, while keytruda is only approved for those patients whose tumors express PD-1 Overall, Bristol Myers Squibb's sales rose 4% in the third quarter, to $4.1 billion In addition to the strong performance of opdivo, eliquis (apixaban), a new oral anticoagulant developed jointly with Pfizer, also performed well, with sales more than double that of the same period in 2014, reaching US $466 million During the same period, the third quarter earnings of MSD amounted to $10.07 billion, an increase of 2% over the same period last year The sales of its diabetes drugs januvia (sitagliptin) and janumet (sitagliptin and metformin) reached US $1.01 billion and US $562 million respectively.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.